Shuangshen granules enhance anti-PD1 therapy effectiveness in lung adenocarcinoma by modulating myeloid-derived suppressor cell-induced T cell exhaustion.

Researchers in China investigated whether a traditional Chinese herbal formula called Shuangshen granules (SSG) could improve the effectiveness of modern cancer immunotherapy for lung cancer. The study used mice with lung tumors to test how SSG works alongside anti-PD-1 therapy, a common immunotherapy drug. Scientists found that SSG helped shrink tumors by improving the immune system's ability to fight cancer. Specifically, the herbal formula reduced "T cell exhaustion" - a condition where immune cells become too tired to attack cancer effectively. It also decreased harmful immune cells called MDSCs that suppress the body's natural cancer-fighting abilities. When combined with anti-PD-1 therapy, SSG showed even better results than either treatment alone. The herbal formula worked in a dose-dependent manner, meaning higher doses produced stronger effects. Using advanced computer analysis, researchers identified five key biological targets and found that SSG likely works through the PI3K-Akt pathway, an important cellular signaling system. The formula also reduced tumor blood vessel formation and cancer cell growth. While this research is promising for understanding how traditional Chinese medicine might support cancer treatment, it's important to note this was an animal study. The findings suggest SSG could potentially help lung cancer patients by enhancing their response to immunotherapy and reducing treatment resistance, though human clinical trials are needed. If you're considering integrating traditional Chinese medicine with cancer treatment, consult with a qualified, licensed acupuncturist and herbalist experienced in oncology support.

This preclinical study examined Shuangshen granules (SSG) combined with anti-PD-1 immunotherapy in Lewis lung carcinoma (LLC) tumor-bearing mice. SSG demonstrated dose-dependent tumor growth inhibition and significantly enhanced anti-PD-1 therapeutic efficacy. Mechanistically, SSG reduced T cell exhaustion markers (PD-1, TIM-3, CTLA-4, LAG-3) and attenuated MDSC-mediated immunosuppression by downregulating Arg-1, IDO, iNOS, PD-L1, and Gal-9 expression. The combination therapy optimized the tumor immune microenvironment more effectively than monotherapy. Network pharmacology identified five hub targets (IL2, STAT3, HSP90AA1, LGALS3, FGF2) with significant enrichment in the PI3K-Akt pathway, which was confirmed via Western blot showing reduced p-PI3K and p-Akt expression. Additional benefits included decreased tumor angiogenesis and proliferation. Assessment methods included IHC, immunofluorescence, flow cytometry, qPCR, and ELISA. These findings provide mechanistic evidence for SSG's role in reversing immunotherapy resistance in lung adenocarcinoma through modulation of the tumor immune microenvironment and PI3K-Akt signaling inhibition.